230 related articles for article (PubMed ID: 25736008)
1. Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in.
Trosman JR; Weldon CB; Kelley RK; Phillips KA
J Natl Compr Canc Netw; 2015 Mar; 13(3):311-8. PubMed ID: 25736008
[TBL] [Abstract][Full Text] [Related]
2. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing.
Trosman JR; Weldon CB; Gradishar WJ; Benson AB; Cristofanilli M; Kurian AW; Ford JM; Balch A; Watkins J; Phillips KA
Value Health; 2018 Sep; 21(9):1062-1068. PubMed ID: 30224110
[TBL] [Abstract][Full Text] [Related]
3. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.
Trosman JR; Douglas MP; Liang SY; Weldon CB; Kurian AW; Kelley RK; Phillips KA
Value Health; 2020 May; 23(5):551-558. PubMed ID: 32389219
[TBL] [Abstract][Full Text] [Related]
4. EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.
Chambers JD; Saret CJ; Anderson JE; Deverka PA; Douglas MP; Phillips KA
Int J Technol Assess Health Care; 2017 Jan; 33(4):534-540. PubMed ID: 29065945
[TBL] [Abstract][Full Text] [Related]
5. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.
Trosman JR; Weldon CB; Douglas MP; Kurian AW; Kelley RK; Deverka PA; Phillips KA
J Natl Compr Canc Netw; 2017 Feb; 15(2):219-228. PubMed ID: 28188191
[No Abstract] [Full Text] [Related]
6. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
Deverka PA; Douglas MP; Phillips KA
Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
[TBL] [Abstract][Full Text] [Related]
7. Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS).
Trosman JR; Weldon CB; Slavotinek A; Norton ME; Douglas MP; Phillips KA
Genet Med; 2020 Feb; 22(2):283-291. PubMed ID: 31501586
[TBL] [Abstract][Full Text] [Related]
8. Clinical integration of next generation sequencing: coverage and reimbursement challenges.
Deverka PA; Dreyfus JC
J Law Med Ethics; 2014; 42 Suppl 1(Suppl 1):22-41. PubMed ID: 25298289
[TBL] [Abstract][Full Text] [Related]
9. US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER).
Phillips KA; Trosman JR; Douglas MP; Gelb BD; Ferket BS; Hindorff LA; Slavotinek AM; Berg JS; Russell HV; Devine B; Greve V; Smith HS
Genet Med; 2022 Jan; 24(1):238-244. PubMed ID: 34906461
[TBL] [Abstract][Full Text] [Related]
10. Health technology assessment and private payers's coverage of personalized medicine.
Trosman JR; Van Bebber SL; Phillips KA
Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP53-60. PubMed ID: 21711078
[TBL] [Abstract][Full Text] [Related]
11. Costs and spillover effects of private insurers' coverage of hepatitis C treatment.
Moreno GA; Mulligan K; Huber C; Linthicum MT; Dreyfus D; Juday T; Marx SE; Gonzalez YS; Brookmeyer R; Lakdawalla DN
Am J Manag Care; 2016 May; 22(6 Spec No.):SP236-44. PubMed ID: 27266954
[TBL] [Abstract][Full Text] [Related]
12. Mapping US commercial payers' coverage policies for medical interventions.
Chambers JD; Chenoweth MD; Neumann PJ
Am J Manag Care; 2016 Sep; 22(9):e323-8. PubMed ID: 27662396
[TBL] [Abstract][Full Text] [Related]
13. Increasing access to next-generation sequencing in oncology for Brazil.
Santos M; Coudry RA; Ferreira CG; Stefani S; Cunha IW; Zalis MG; Araujo LH
Lancet Oncol; 2019 Jan; 20(1):20-23. PubMed ID: 30614460
[No Abstract] [Full Text] [Related]
14. US payer perspectives on evidence for formulary decision making.
Wang A; Halbert RJ; Baerwaldt T; Nordyke RJ
Am J Manag Care; 2012 May; 18(5 Spec No. 2):SP71-6. PubMed ID: 22693984
[TBL] [Abstract][Full Text] [Related]
15. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.
Trosman JR; Weldon CB; Douglas MP; Deverka PA; Watkins JB; Phillips KA
Value Health; 2017 Jan; 20(1):40-46. PubMed ID: 28212967
[TBL] [Abstract][Full Text] [Related]
16. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
17. Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay.
Trosman JR; Van Bebber SL; Phillips KA
J Oncol Pract; 2010 Sep; 6(5):238-42. PubMed ID: 21197187
[TBL] [Abstract][Full Text] [Related]
18. Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019.
Douglas MP; Gray SW; Phillips KA
J Natl Compr Canc Netw; 2020 Jul; 18(7):866-872. PubMed ID: 32634780
[TBL] [Abstract][Full Text] [Related]
19. Scenario drafting for early technology assessment of next generation sequencing in clinical oncology.
Joosten SEP; Retèl VP; Coupé VMH; van den Heuvel MM; van Harten WH
BMC Cancer; 2016 Feb; 16():66. PubMed ID: 26851938
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
